Inhibrx Biosciences Inc (INBX) financials
Inhibrx Biosciences revenue and earnings by year
Inhibrx Biosciences's revenue was $1.30 million in the fiscal year to December 31, 2025, up 550.0% from the year before. Net income was -$140 million, -10773.5% of revenue. Since the fiscal year to December 31, 2022, revenue has shrunk 16.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue growth | 550.0% | -88.9% | -17.9% | — |
| Operating income | -0.14 | -0.33 | -0.22 | -0.13 |
| Operating margin | -10386.5% | -165724.0% | -12178.9% | -5890.4% |
| Net income | -0.14 | 1.69 | -0.24 | -0.15 |
| Net margin | -10773.5% | 843786.0% | -13408.9% | -6625.3% |
| Diluted EPS | -$9.04 | $112.62 | — | — |
| Free cash flow | -0.13 | -0.20 | -0.20 | -0.12 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open INBX in Markets.
See also: INBX returns
No forecast, no recommendation. This page describes Inhibrx Biosciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.